Emmaus Life Sciences, Inc.
Income Statement
| Line Item | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $5.4M | $2.5M | $7.1M | $5.0M | $10.8M | $6.8M | $5.9M | $4.9M |
| Cost of Revenue | $241.0K | $257.0K | $191.0K | $214.0K | $508.0K | $429.0K | $645.0K | $540.0K |
| Gross Profit | $5.1M | $2.2M | $6.9M | $4.8M | $10.3M | $6.3M | $5.3M | $4.4M |
| Gross Margin | 95.5% | 89.7% | 97.3% | 95.7% | 95.3% | 93.6% | 89.1% | 89.1% |
| Operating Expenses | ||||||||
| Research & Development | $191.0K | $183.0K | $166.0K | $414.0K | $320.0K | $289.0K | $529.0K | $432.0K |
| SG&A Expense | $2.7M | $2.9M | $3.1M | $2.9M | $4.1M | $4.9M | $3.8M | $3.0M |
| Operating Income | $582.0K | $-2.7M | $1.4M | $24.0K | $3.3M | $-1.2M | $-1.4M | $-660.0K |
| Operating Margin | 10.8% | -109.3% | 19.2% | 0.5% | 30.9% | -17.3% | -23.9% | -13.4% |
| Interest Expense | $966.0K | $1.9M | $2.2M | $1.9M | $1.8M | $1.5M | $1.5M | $1.5M |
| Pretax Income | $-2.2M | $-4.4M | $1.1M | $105.0K | $-1.6M | $-3.4M | $216.0K | $-426.0K |
| Income Tax Expense | $31.0K | $-7.0K | $-112.0K | $38.0K | $-34.0K | $49.0K | $16.0K | $-35.0K |
| Net Income | $-2.2M | $-4.3M | $1.2M | $67.0K | $-1.6M | $-3.5M | $200.0K | $-391.0K |
| Net Margin | -40.6% | -173.5% | 17.1% | 1.3% | -14.5% | -51.1% | 3.4% | -7.9% |
| EPS (Basic) | $-0.03 | $-0.07 | $0.03 | $0.00 | $-0.03 | $-0.07 | $0.01 | $-0.01 |
| EPS (Diluted) | $-0.03 | $-0.07 | $0.04 | $-0.01 | $-0.03 | $-0.07 | $0.01 | $-0.01 |
| Shares Outstanding (Basic) | 63.4M | 61.8M | 53.1M | 53.6M | 52.9M | 50.7M | 49.4M | 49.6M |
| Shares Outstanding (Diluted) | 63.4M | 61.8M | 53.1M | 138.4M | 52.9M | 50.7M | 49.4M | 49.6M |
| Dividends Per Share | — | — | — | — | — | — | — | — |